Previous 10 | Next 10 |
2023-12-17 17:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2023 financial results for the period ended September 30, 2023. “During the third quarter we saw interest income on our cash and short term inve...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Merrimack Pharmaceuticals Inc. (MACK) is expected to report for Q1 2024
2023-09-19 12:25:41 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 19, 2023 – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding f...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2023 financial results for the period ended June 30, 2023. “We were excited to see the announcement from Ipsen that the U.S. Food and Drug Admi...
2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...
2023-05-04 17:47:44 ET Merrimack Pharmaceuticals press release ( NASDAQ: MACK ): Q1 GAAP EPS of $0.02. Merrimack reported a gain on the sale of assets for the first quarter ended March 31, 2023, of $139 thousand, attributable to an asset purchase option agreement on a pr...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023. “During the first quarter of 2023 our operating expenses remained consistent with pr...
2023-03-09 16:58:50 ET Merrimack Pharmaceuticals press release ( NASDAQ: MACK ): FY GAAP EPS of -$0.11. As of December 31, 2022, Merrimack had cash and cash equivalents of $19.4 million, compared to $14.2 million as of December 31, 2021 For further details see: M...
News, Short Squeeze, Breakout and More Instantly...
Merrimack Pharmaceuticals Inc. Company Name:
MACK Stock Symbol:
NASDAQ Market:
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has filed notice with NASDAQ of the Companyȁ...
2024-04-13 01:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...